|  |  | 

India Top Headlines

2DG Medicine From DRDO: Everything You Need To Know About 2-Deoxy-D-Glucose (2DG) Price, Uses And Side Effects | India News


NEW DELHI: Defense Minister Rajnath Singh and Union Health Minister Dr. Harsh Vardhan on Monday launched the first batch of anti-COVID drug 2-deoxy-D-glucose (2-DG) developed by the Defense Research and Development Organization (DRDO).
The drug’s anti-Covid therapeutic application has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad.
Earlier this month, the General Controller of Drugs of India (DGCI) approved the oral drug for emergency use as add-on therapy in patients with moderate to severe coronavirus. The drug’s approval came at a time when India is dealing with a record wave of the coronavirus pandemic that has pushed the country’s healthcare infrastructure to the limit.
DRDO President Dr. G Satheesh Reddy said that DRDO and Dr. Reddy’s lab had gone through the full tests and performed them in 30 hospitals and on a large number of patients.
The medicine comes as a powder in a sachet, which is taken by mouth by dissolving it in water. It accumulates in cells infected by the virus and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virus-infected cells makes this drug unique.
Results of clinical trials have shown that this drug helps in faster recovery in hospitalized patients and reduces dependence on supplemental oxygen. A higher proportion of patients treated with 2-DG showed negative conversion of RT-PCR in patients with Covid.
In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of the Center for Cellular and Molecular Biology (CCMB), Hyderabad, and found that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth.
He said that based on these results, the Medicines Controller and the Central Medicines Control Organization (CDSCO) allowed the phase II clinical trial of 2-DG in patients with Covid-19 in May 2020.
The DRDO, together with its industrial partner DRL, Hyderabad, initiated clinical trials to test the drug’s safety and efficacy in Covid-19 patients.
In Phase II trials (including dose range) conducted during May-October 2020, the drug was found to be safe in Covid patients and showed significant improvement in their recovery, the ministry statement said, adding that the Phase II was conducted in six hospitals and the Phase IIb (dose range) clinical trial was conducted in 11 hospitals across the country.
In efficacy trends, patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on several endpoints. A significantly favorable trend (2.5 day difference) was observed in terms of the median time to achieve normalization of specific vital signs parameters compared to SoC.
In November 2020, phase 3 trials were approved and continued from December to April. On May 1, the drug was approved for emergency use. Dr Reddy’s Labs is dedicated to its production.
Based on successful results, DCGI further enabled phase III clinical trials in November 2020. The phase III clinical trial was conducted in 220 patients between December 2020 and March 2021 at 27 Covid hospitals in Delhi, Uttar Pradesh , West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu. Detailed data from the phase III clinical trial were submitted to DCGI. In the 2-DG arm, a significantly greater proportion of patients improved symptomatically and were released from supplemental oxygen dependence (42% vs. 31%) by day 3 compared to SoC, indicating early relief of the oxygen therapy / dependence.
On May 1, 2021, DCGI granted permission for the emergency use of this drug as an adjunct therapy in patients with moderate to severe Covid-19.
(With inputs from agencies)

Original source